Towards a holographic dual of large-N_c QCD

We study N_f D6-brane probes in the supergravity background dual to N_c D4-branes compactified on a circle with supersymmetry-breaking boundary conditions. In the limit in which the resulting Kaluza--Klein modes decouple, the gauge theory reduces to non-supersymmetric, four-dimensional QCD with N_c colours and N_f << N_c flavours. As expected, this decoupling is not fully realised within the supergravity/Born--Infeld approximation. For N_f = 1 and massless quarks, m_q = 0, we exhibit spontaneous chiral symmetry breaking by a quark condensate, \neq 0, and find the associated massless `pion' in the spectrum. The latter becomes massive for m_q > 0, obeying the Gell-Mann--Oakes--Renner relation: M_pi^2= - m_q / \f_pi^2. In the case N_f > 1 we provide a holographic version of the Vafa--Witten theorem, which states that the U(N_f) flavour symmetry cannot be spontaneously broken. Further we find N_f^2 - 1 unexpectedly light pseudo-scalar mesons in the spectrum. We argue that these are not (pseudo) Goldstone bosons and speculate on the string mechanism responsible for their lightness. We then study the theory at finite temperature and exhibit a phase transition associated with a discontinuity in the chiral condensate. D6/anti-D6 pairs are also briefly discussed.Comment: 43 pages, LaTeX; v3: Scalar vs. pseudo-scalar nature of mesons clarified, references added. v4: Small change in Acknowledgment

Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains

Cast nephropathy is the most common cause of renal disease in multiple myeloma, however, treatment with plasma exchange remains controversial even after 3 randomized controlled studies. We sought to determine the importance of diagnostic confirmation and goal directed therapy in the treatment of cast nephropathy in forty patients with confirmed multiple myeloma and renal failure who underwent plasma exchange. A positive renal response was defined as a decrease by half in the presenting serum creatinine and dialysis independence. No baseline differences were noted between eventual renal responders and non-responders. Three quarters of the patients with biopsy proven cast nephropathy resolved their renal disease when the free light chains present in the serum were reduced by half or more but there was no significant response when the reduction was less. The median time to a response was about 2 months. In patients without cast nephropathy, renal recovery occurred despite reductions in free light chain levels of the serum. No association was found between free light chains in the serum, urinary monoclonal proteins, overall proteinuria and cast nephropathy. We found that the relationship between renal recovery and free light chain reduction was present only in patients with biopsy proven cast nephropathy showing the importance of extracorporeal light chain removal in this disease

The Young Planetary System K2-25: Constraints on Companions and Starspots

The abundance of planets with orbital periods of a few to tens of days suggests that exoplanets experience complex dynamical histories. Planets in young stellar clusters or associations have well-constrained ages and therefore provide an opportunity to explore the dynamical evolution of exoplanets. K2-25b is a Neptune-sized planet in an eccentric, 3.48 day orbit around an M4.5 dwarf star in the Hyades cluster (650 Myr). In order to investigate its non-zero eccentricity and tight orbit, we analyze transit timing variations (TTVs) which could reveal clues to the migration processes that may have acted on the planet. We obtain 12 nonconsecutive transits using the MEarth observatories and long-term photometric monitoring, which we combine with 10 transits from the Spitzer Space Telescope and 20 transits from K2. Tables of MEarth photometry accompany this work. We fit each transit lightcurve independently. We first investigate whether inhomogeneities on the stellar surface (such as spots or plages) are differentially affecting our transit observations. The measured transit depth does not vary significantly between transits, though we see some deviations from the fiducial transit model. We then looked for TTVs as evidence of a nontransiting perturber in the system. We find no evidence for >1 M ? mass companions within a 2:1 period ratio, or for >5 M ? mass planets within a 7:2 period ratio

Meson Spectroscopy in AdS/CFT with Flavour

We compute the meson spectrum of an N=2 super Yang-Mills theory with fundamental matter from its dual string theory on AdS_5 x S_5 with a D7-brane probe. For scalar and vector mesons with arbitrary R-charge the spectrum is computed in closed form by solving the equations for D7-brane fluctuations; for matter with non-zero mass m_q it is discrete, exhibits a mass gap of order m_q / sqrt(g_s N) and furnishes representations of SO(5) even though the manifest global symmetry of the theory is only SO(4). The spectrum of mesons with large spin J is obtained from semiclassical, rotating open strings attached to the D7-brane. It displays Regge-like behaviour for J << sqrt(g_s N), whereas for J >> sqrt(g_s N) it corresponds to that of two non-relativistic quarks bound by a Coulomb potential. Meson interactions, baryons and `giant gauge bosons' are briefly discussed.Comment: LaTeX, 39 pages, 4 figures, uses epsf. v2: typos corrected. references adde

A pair of tess planets spanning the radius valley around the nearby mid-m dwarf ltt 3780

We present the confirmation of two new planets transiting the nearby mid-M dwarf LTT 3780 (TIC 36724087, TOI-732, V = 13.07, K s = 8.204, R s = 0.374 R o˙, M s = 0.401 M o˙, d = 22 pc). The two planet candidates are identified in a single Transiting Exoplanet Survey Satellite sector and validated with reconnaissance spectroscopy, ground-based photometric follow-up, and high-resolution imaging. With measured orbital periods of P b = 0.77, P c = 12.25 days and sizes r p,b = 1.33 ± 0.07, r p,c = 2.30 ± 0.16 R ⊕, the two planets span the radius valley in period-radius space around low-mass stars, thus making the system a laboratory to test competing theories of the emergence of the radius valley in that stellar mass regime. By combining 63 precise radial velocity measurements from the High Accuracy Radial velocity Planet Searcher (HARPS) and HARPS-N, we measure planet masses of mpb 2.62+ 0.48 and-0.46= mpc 8.6+1.6-1.3 M⊕, which indicates that LTT 3780b has a bulk composition consistent with being Earth-like, while LTT 3780c likely hosts an extended H/He envelope. We show that the recovered planetary masses are consistent with predictions from both photoevaporation and core-powered mass-loss models. The brightness and small size of LTT 3780, along with the measured planetary parameters, render LTT 3780b and c as accessible targets for atmospheric characterization of planets within the same planetary system and spanning the radius valley

/sup 187/Os + n resonance parameters in the interval 27-500 eV neutron energies

The neutron total cross section for /sup 187/Os, in the energy range, 27 eV to 500 eV, has been measured at the ORELA facility by the neutron time-of-flight technique, utilizing a 2.0 gm osmium sample (n = 0.008401 Os-nuclei/barn) enriched to 70.38% /sup 187/Os. Measurements were performed at a 80 m flight station with an energy resolution, ..delta..E/E, of 0.1% using a /sup 6/Li glass scintillator. Resolved resonances have been analyzed by a Reich-Moore multilevel code (SAMMY) to obtain parameters for 85 resonances up to 500 eV. Preliminary determinations of the level spacing (5 eV) and s-wave strength function (3.9 x 10/sup -4/) for /sup 187/Os are in agreement with recent analyses of the osmium isotopes, made in connection with the use of the Re/Os chronometer for estimating the duration of stellar nucleosynthesis

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg

Prasugrel is a third-generation thienopyridine platelet P2Y12 adenosine diphosphate (ADP) receptor antagonist administered with aspirin for the treatment of patients with acute coronary syndrome (ACS) with planned percutaneous coronary intervention. Prasugrel is administered periprocedurally at an oral loading dose of 60 mg followed by daily maintenance doses (MDs) of 10 mg for most patients and 5 mg for patients weighing &amp;lt;60 kg or aged ≥75 years. Data from a prasugrel phase III study, TRITON-TIMI 38, suggested that a lower MD might be more suitable for patients weighing &amp;lt;60 kg or aged ≥75 years; subsequent pharmacokinetic and pharmacodynamic studies have indicated that prasugrel 5 mg reduced platelet reactivity in these populations to an extent similar to that of prasugrel 10 mg in heavier or younger patients. Clinical experience with prasugrel 5 mg is limited, and additional studies are needed to verify the clinical efficacy and safety of this dose in these challenging populations. © 2016, Springer International Publishing Switzerland